Poseida Therapeutics (PSTX) Stock Forecast, Price Target & Predictions
PSTX Stock Forecast
Poseida Therapeutics stock forecast is as follows: an average price target of $15.00 (represents a 441.52% upside from PSTX’s last price of $2.77) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PSTX Price Target
The average price target for Poseida Therapeutics (PSTX) is $15.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 441.52% upside from PSTX's last price of $2.77.
PSTX Analyst Ratings
According to 2 Wall Street analysts, Poseida Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PSTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Poseida Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 04, 2023 | - | H.C. Wainwright | $15.00 | $5.79 | 159.07% | 441.52% |
The latest Poseida Therapeutics stock forecast, released on Jan 04, 2023 by H.C. Wainwright company, set a price target of $15.00, which represents a 159.07% increase from the stock price at the time of the forecast ($5.79), and a 441.52% increase from PSTX last price ($2.77).
Poseida Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $2.77 | $2.77 | $2.77 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Poseida Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Poseida Therapeutics's last price of $2.77. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Poseida Therapeutics's last stock rating was published by H.C. Wainwright on Oct 17, 2024. The company gave PSTX a "Buy" rating, the same as its previous rate.
Poseida Therapeutics Financial Forecast
Poseida Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $25.00M | $9.35M | $20.01M | $10.34M | $9.92M | $116.31M | $2.70M | $1.44M | $31.24 | - |
| Avg Forecast | $93.35M | $90.66M | $88.05M | $85.51M | $7.50M | $7.50M | $7.50M | $7.50M | $21.25M | $16.25M | $15.42M | $11.67M | $6.65M | $18.87M | $6.78M | $9.38M | $61.69M | $1.25M | $1.40M | $478.33K | $23.13M | $3.63M |
| High Forecast | $119.17M | $115.73M | $112.40M | $109.16M | $9.57M | $9.57M | $9.57M | $9.57M | $28.33M | $20.74M | $15.42M | $14.89M | $8.49M | $18.87M | $8.66M | $11.97M | $78.75M | $1.25M | $1.40M | $478.33K | $23.13M | $4.35M |
| Low Forecast | $71.50M | $69.44M | $67.44M | $65.50M | $5.74M | $5.74M | $5.74M | $5.74M | $14.17M | $12.45M | $15.42M | $8.94M | $5.09M | $18.87M | $5.19M | $7.18M | $47.25M | $1.25M | $1.40M | $478.33K | $23.13M | $2.90M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.76% | 0.50% | 2.95% | 1.10% | 0.16% | 93.04% | 1.93% | 3.00% | 0.00% | - |
Poseida Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $11.67M, with a low forecast of $8.94M, and a high forecast of $14.89M. PSTX's average Quarter revenue forecast represents a -53.32% decrease compared to the company's last Quarter revenue of $25.00M (Dec 23).
Poseida Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-46.18M | $-36.22M | $-27.86M | $-36.82M | $-31.05M | $73.79M | $-40.23M | $-55.77M | $123.80K | $-29.09M |
| Avg Forecast | $-7.84M | $-7.62M | $-7.40M | $-7.19M | $-630.25K | $-630.25K | $-630.25K | $-630.25K | $-1.79M | $-1.37M | $-1.30M | $-980.40K | $-558.83K | $-1.59M | $-569.75K | $-787.82K | $-5.18M | $-109.48K | $-122.62K | $-36.25M | $-2.03M | $-14.66M |
| High Forecast | $-6.01M | $-5.84M | $-5.67M | $-5.50M | $-482.75K | $-482.75K | $-482.75K | $-482.75K | $-1.19M | $-1.05M | $-1.30M | $-750.94K | $-428.04K | $-1.59M | $-436.40K | $-603.43K | $-3.97M | $-109.48K | $-122.62K | $-29.00M | $-2.03M | $-11.73M |
| Low Forecast | $-10.01M | $-9.73M | $-9.45M | $-9.17M | $-804.58K | $-804.58K | $-804.58K | $-804.58K | $-2.38M | $-1.74M | $-1.30M | $-1.25M | $-713.39K | $-1.59M | $-727.34K | $-1.01M | $-6.62M | $-109.48K | $-122.62K | $-43.50M | $-2.03M | $-17.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 82.64% | 22.85% | 48.89% | 46.74% | 5.99% | -673.97% | 328.12% | 1.54% | -0.06% | 1.98% |
1 analysts predict PSTX's average Quarter EBITDA for Dec 22 to be $-5.18M, with a high of $-3.97M and a low of $-6.62M. This is -107.03% lower than Poseida Therapeutics's previous annual EBITDA (Sep 22) of $73.79M.
Poseida Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-23.99M | $-31.78M | $-27.46M | $-40.21M | $-33.32M | $70.41M | $-44.53M | $-59.15M | $17.73M | $-30.43M |
| Avg Forecast | $-22.80M | $-22.42M | $-22.05M | $-21.52M | $-37.00M | $-45.84M | $-49.77M | $-45.84M | $-32.41M | $-41.01M | $-39.95M | $-41.25M | $-37.91M | $-28.81M | $-51.86M | $-44.25M | $16.67M | $-63.27M | $-73.94M | $-37.74M | $-33.70M | $-15.38M |
| High Forecast | $-15.86M | $-15.60M | $-15.34M | $-14.97M | $-25.74M | $-31.89M | $-34.62M | $-28.28M | $-25.21M | $-28.53M | $-27.79M | $-28.70M | $-16.85M | $-20.05M | $-36.08M | $-30.79M | $22.66M | $-63.27M | $-73.94M | $-30.19M | $-33.70M | $-12.30M |
| Low Forecast | $-30.99M | $-30.49M | $-29.98M | $-29.26M | $-50.30M | $-62.32M | $-67.66M | $-63.39M | $-45.02M | $-55.75M | $-54.31M | $-56.09M | $-52.66M | $-39.17M | $-70.51M | $-60.17M | $11.59M | $-63.27M | $-73.94M | $-45.28M | $-33.70M | $-18.45M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.63% | 1.10% | 0.53% | 0.91% | -2.00% | -1.11% | 0.60% | 1.57% | -0.53% | 1.98% |
Poseida Therapeutics's average Quarter net income forecast for Dec 22 is $16.67M, with a range of $11.59M to $22.66M. PSTX's average Quarter net income forecast represents a -76.33% decrease compared to the company's last Quarter net income of $70.41M (Sep 22).
Poseida Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.86M | $8.09M | $8.68M | $11.81M | $9.37M | $9.39M | $9.24M | $9.55M | $-26.27K | $4.24M |
| Avg Forecast | $74.98M | $72.82M | $70.72M | $68.68M | $6.02M | $6.02M | $6.02M | $6.02M | $17.07M | $13.05M | $12.38M | $9.37M | $5.34M | $15.15M | $5.45M | $7.53M | $49.55M | $1.00M | $1.12M | $384.22K | $18.58M | $2.14M |
| High Forecast | $95.72M | $92.96M | $90.28M | $87.68M | $7.69M | $7.69M | $7.69M | $7.69M | $22.76M | $16.66M | $12.38M | $11.96M | $6.82M | $15.15M | $6.95M | $9.61M | $63.26M | $1.00M | $1.12M | $384.22K | $18.58M | $2.57M |
| Low Forecast | $57.43M | $55.78M | $54.17M | $52.61M | $4.61M | $4.61M | $4.61M | $4.61M | $11.38M | $10.00M | $12.38M | $7.18M | $4.09M | $15.15M | $4.17M | $5.77M | $37.95M | $1.00M | $1.12M | $384.22K | $18.58M | $1.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.66% | 0.53% | 1.59% | 1.57% | 0.19% | 9.35% | 8.21% | 24.85% | -0.00% | 1.98% |
Poseida Therapeutics's average Quarter SG&A projection for Mar 24 is $9.37M, based on 1 Wall Street analysts, with a range of $7.18M to $11.96M. The forecast indicates a 5.77% rise compared to PSTX last annual SG&A of $8.86M (Dec 23).
Poseida Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.00 | $-0.47 | $-0.39 | $0.92 | $-0.71 | $-0.95 | $0.28 | $-0.53 |
| Avg Forecast | $-0.23 | $-0.23 | $-0.22 | $-0.22 | $-0.38 | $-0.47 | $-0.51 | $-0.47 | $-0.33 | $-0.42 | $-0.41 | $-0.42 | $-0.39 | $-0.29 | $-0.53 | $-0.45 | $0.17 | $-0.65 | $-0.76 | $-0.73 | $-0.35 | $-1.15 |
| High Forecast | $-0.16 | $-0.16 | $-0.16 | $-0.15 | $-0.26 | $-0.32 | $-0.35 | $-0.29 | $-0.26 | $-0.29 | $-0.28 | $-0.29 | $-0.17 | $-0.20 | $-0.37 | $-0.31 | $0.23 | $-0.65 | $-0.76 | $-0.73 | $-0.35 | $-1.15 |
| Low Forecast | $-0.32 | $-0.31 | $-0.31 | $-0.30 | $-0.51 | $-0.63 | $-0.69 | $-0.65 | $-0.46 | $-0.57 | $-0.55 | $-0.57 | $-0.54 | $-0.40 | $-0.72 | $-0.61 | $0.12 | $-0.65 | $-0.76 | $-0.73 | $-0.35 | $-1.15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 1.04% | -2.30% | -1.41% | 0.93% | 1.31% | -0.81% | 0.46% |
According to 1 Wall Street analysts, Poseida Therapeutics's projected average Quarter EPS for Dec 22 is $0.17, with a low estimate of $0.12 and a high estimate of $0.23. This represents a -81.56% decrease compared to PSTX previous annual EPS of $0.92 (Sep 22).
Poseida Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| PASG | Passage Bio | $0.48 | $6.00 | 1150.00% | Buy |
| IPSC | Century Therapeutics | $1.28 | $15.00 | 1071.88% | Buy |
| ANTX | AN2 Therapeutics | $1.06 | $8.75 | 725.47% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.26 | $10.00 | 693.65% | Buy |
| PEPG | PepGen | $4.47 | $29.50 | 559.96% | Buy |
| PSTX | Poseida Therapeutics | $2.77 | $15.00 | 441.52% | Buy |
| MOLN | Molecular Partners | $5.46 | $29.00 | 431.14% | Buy |
| CUE | Cue Biopharma | $1.08 | $4.33 | 300.93% | Buy |
| PLRX | Pliant Therapeutics | $12.79 | $39.71 | 210.48% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
| MLYS | Mineralys Therapeutics | $12.86 | $30.00 | 133.28% | Buy |
| PHVS | Pharvaris | $20.51 | $39.67 | 93.42% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| DYN | Dyne Therapeutics | $29.68 | $43.88 | 47.84% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $56.47 | $60.63 | 7.37% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |